BiomeBank is a clinical stage biotechnology company developing microbial therapies to treat unmet medical need globally, with an immediate focus on the APAC region. We currently manufacture a microbial therapy to treat Clostridoides difficile, a potentially life threatening infection, and are positioning the drug product for multiple indications.Furthermore, we are actively developing second generation therapies in multiple diseases, including Ulcerative Colitis and Crohn's Disease.

Biotechnology

BiomeBank

Sam Costello

Corey Whittle

Philippa C.

Sarah Haylock-Jacobs

Paul Flynn FUniSA, MAICD, FFIA

Lisa Kirkland

Johnathon Matthews

Garrett Heiman

Chelsea Bickley

Research and Development Team

Quality Assurance and Regulatory Affairs

Teams at BiomeBank

Research and Development Team

Quality Assurance and Regulatory Affairs